1

Summary

text

Infertility and Assisted Reproductive Technology (ART) Overview

Definitions & Epidemiology

• Infertility is defined as the inability of a couple to achieve pregnancy within one year of unprotected frequent sexual contact.
• Early Infertility evaluation (after 6 months) is warranted for women >35 years old or those with oligo/amenorrhea, known tubal disease, severe endometriosis, or male factors.
• Fecundability is the monthly ability of a normal fertile couple to get pregnant, typically approximately 20%.
• Female Infertility factors account for 54% of cases, with Ovulatory Disorders (27%) and Tubal Disorders (22%) being the most common.
• Unexplained Infertility occurs in approximately 17-20% of couples where all standard diagnostic tests are normal.
• Infertility prevalence increases with the age of the female partner: 1 in 7 if age 30-34, 1 in 5 if age 35-40, and 1 in 4 if age 40-44.
• Azoospermic husbands: Even with donor insemination, the pregnancy rate in women decreases from 73% (age <25) to 55.8% (age 36-40).
• Diminished Ovarian Reserve is the most common diagnostic category among women undergoing IVF.

Physiology & Optimal Timing

• Oocyte lifespan: An egg disintegrates less than 24 hours after reaching the ampulla.
• Sperm lifespan: Normal sperm retain fertilizing ability in the oviduct for up to 72 hours.
• Optimal conception time: Intercourse on the day before ovulation or daily for 3 days at mid-cycle yields the highest pregnancy rate (30%).
• LH Surge detection (First morning urine): If positive, ovulation occurs on the same day of detection.
• LH Surge detection (Random urine): Ovulation occurs 12 to 24 hours after a positive result (the suivant day).
• Conception blockers: Vaginal lubricants, saliva, cigarette smoking, and douching decrease the chance of conception.

Ovulation & Ovarian Reserve Assessment

• Serum Progesterone (Midluteal phase): Values >3-5 ng/mL suggest some ovulatory function; ≥10 ng/mL suggests a normal ovulatory cycle and potential conception.
• Basal Body Temperature (BBT): Based on the thermogenic effect of progesterone on the hypothalamus; requires taking sublingual temperature shortly after awakening after 6 hours of sleep.
• Endometrial Biopsy: Formerly used to diagnose luteal phase defects, but is no longer indicated for routine infertility workup because it is invasive and subjective.
• Ovarian Reserve Testing: Primarily recommended for women >35, those with unexplained infertility, smokers, or those with a history of ovarian surgery/chemo/radiation.
• Serum FSH (Day 2 or 3): Elevated levels (>10 mIU/mL) indicate decreased ovarian reserve; >20 mIU/mL indicates a poor prognosis.
• Serum Estradiol (E2): Levels >70 pg/mL early in the cycle suggest poor prognosis or may invalidate FSH readings.
• Anti-Müllerian Hormone (AMH): Produced by granulosa cells; <0.5 ng/mL indicates decreased ovarian reserve, while >2 ng/mL indicates more follicles are available.
• AMH Menopause prediction: An AMH level of 0.05 ng/mL suggests menopause will occur within 4-5 years.
• Antral Follicle Count (AFC): Measured via TVS on cycle day 2 to 4; a count of 10 or more follicles (2-10 mm size) suggests good ovarian reserve.

Semen Analysis & Male Evaluation

• Male Infertility workup: Includes 2-3 days of abstinence before semen collection; entire specimen should be collected in a wide-mouthed jar.
• Sperm motility: Begins to decline 2 hours after ejaculation; specimen must be examined within this period and kept warm.
• Sperm morphology: A subjective test reflecting sperm production from 3 months prior; only normal forms (Kruger criteria 4%) have fertilization ability.
• Low normal sperm values (WHO 2010): Concentration 15 million/mL, total number 39 million/ejaculate, and 40% motility.
• Intrauterine Insemination (IUI): Sperm must be washed and separated from seminal fluid; Unwashed seminal fluid must NOT be used because it contains prostaglandins that cause severe uterine cramps and infection.
• IUI Limitations: Less successful if significant oligospermia (<5 million motile sperm) is present.

Hysterosalpingography (HSG) & Tubal Disease

• HSG Timing: Performed on the 10th day of the cycle (follicular phase) to avoid pregnancy and ensure better endometrial definition.
• HSG Contraindications: History of untreated salpingitis or tenderness on pelvic exam.
• Water-soluble contrast: Currently preferred over oil-soluble contrast to avoid peritoneal irritation and granulomas.
• Doxycycline (100 mg BID): Prophylactic antibiotic given for 1-2 weeks if hydrosalpinx is visualized on HSG.
• Hydrosalpinx (HSG): Appears as distal blockage with "ballooning" and a sausage-like appearance; spillage of dye is absent.
• Proximal Tubal Obstruction: May be due to true block (SIN, infection) or cornual spasm (false block).
• Laparoscopic Salpingectomy: Recommended prior to IVF for women with large hydrosalpinx because the fluid affects embryo implantation and decreases IVF success rates by 40%.
• Tubal wall thickness: The best prognostic factor for pregnancy after tubal reconstructive surgery.
• Tubal Tuberculosis: Radiographically appears as a "pipe stem" configuration; women with pelvic TB are considered sterile.

Medical Management of Anovulation

• Clomiphene Citrate (CC): A selective estrogen receptor antagonist; first-line for oligomenorrhea with sufficient estrogen. Dose is 50-150 mg for 5 days starting on day 3-5.
• Clomiphene side effects: 8% incidence of multiple gestations, ovarian cysts, vasomotor flushes, hair loss, and blurring of vision.
• "Stair-step" CC Regimen: If no follicle develops, the dose is increased immediately within the same cycle to avoid waiting for menses.
• Letrozole: An aromatase inhibitor; preferred over CC in PCOS patients due to higher live birth rates and lower multiple pregnancy rates.
• Metformin: An insulin-sensitizing biguanide used as an adjunct in obese PCOS patients; start "low and slow" to minimize GI side effects (nausea/vomiting).
• Gonadotropins (FSH/HMG): Used when patients are unresponsive to CC/Letrozole; requires ultrasound monitoring to prevent OHSS.
• HCG (5,000-10,000 IU): Used as a "trigger" to induce ovulation, which occurs 36-48 hours after administration.
• Dopamine Agonists: Specific treatment for anovulation caused by Hyperprolactinemia.

Ovarian Hyperstimulation Syndrome (OHSS)

• OHSS Pathogenesis: Excessive ovarian stimulation leads to high E2 and VEGF secretion, causing increased vascular permeability and massive fluid shifts.
• OHSS Mild: Ovarian enlargement ≤5 cm with abdominal discomfort.
• OHSS Moderate: Ovarian enlargement 6-10 cm, nausea/GI symptoms, and mild ascites (not clinically evident).
• OHSS Severe: Clinically evident ascites, hydrothorax, hematocrit >45%, and increased WBC. Requires hospitalization.
• OHSS Critical: Oliguria, creatinine >1.6 mg/dL, thrombosis, infection, and potential DIC.
• OHSS Prevention: Use of GnRH agonist trigger instead of HCG, lowering gonadotropin doses, or "coasting."

In-Vitro Fertilization (IVF) Specifics

• IVF Indications: Blocked tubes, severe male factor, advanced maternal age, unexplained infertility failed IUI, and genetic screening.
• Intracytoplasmic Sperm Injection (ICSI): Single sperm injection into a mature oocyte; preferred for male factor infertility, prior failed fertilization, and frozen oocytes.
• Oocyte Harvesting: Performed 34-36 hours after HCG trigger; requires at least 3 mature follicles (≥18 mm) on ultrasound.
• Embryo Transfer (Day 3 vs Day 5): Blastocysts (Day 5) have higher implantation and pregnancy rates than cleavage-stage (Day 3) embryos.
• Assisted Hatching (AH): Drilling a hole in the zona pellucida with laser/acid; useful for older women (>37) but increases risk of monozygotic twinning.
• Elective Single Embryo Transfer (eSET): Recommended for women <35 to minimize the risk of high-risk multifetal pregnancies.
• In-Vitro Maturation (IVM): Harvesting immature eggs to mature them outside the body; primarily used in PCOS to eliminate OHSS risk.
• Frozen Embryo Transfer (FET): Requires estrogen therapy to prime the endometrium and progesterone supplementation 4-6 days before transfer.
• Recurrent Implantation Failure: Defined as 3 failed transfers of good embryos or 2 failed transfers of euploid blastocysts; may require Endometrial Receptivity Analysis (ERA).

Genetic Testing & Fertility Preservation

• PGT-A: Genetic testing for aneuploidy (abnormal chromosome number); recommended for advanced maternal age (>37) or recurrent loss.
• PGT-M: Genetic testing for monogenic diseases (e.g., Cystic Fibrosis, Tay-Sachs, Huntington’s).
• Trophectoderm Biopsy: The preferred method for PGT, performed on Day 5 or 6 blastocysts.
• Social Freezing: Oocyte cryopreservation in healthy young women to delay childbearing and mitigate the age effect on fecundity.
• GnRH agonist (in chemotherapy): Administered 7-10 days before chemo to protect ovaries by suppressing the HPG axis and reducing blood flow.
• Ovarian tissue cryopreservation: Option for cancer patients, but contraindicated in leukemias due to the risk of malignant cell re-seeding.

Differentiating Similar Entities & Exam High-Yield Points

1. Fecundability (20%) is the monthly probability of pregnancy, whereas Fecundity is the monthly probability of a live birth.
2. LH Test (First morning urine) means ovulation is now (today); LH Test (Random urine) means ovulation is tomorrow (12-24 hours).
3. Clomiphene Citrate is an estrogen receptor antagonist (systemic); Letrozole is an aromatase inhibitor (inhibits conversion to estrogen).
4. Letrozole is superior to Clomiphene specifically in PCOS patients; they are roughly equal in unexplained infertility.
5. Serum Progesterone >3 ng/mL proves ovulation happened; Serum Progesterone ≥10 ng/mL is the threshold for healthy spontaneous conception.
6. Hydrosalpinx vs. Salpingitis Isthmica Nodosa (SIN): Hydrosalpinx is distal ballooning; SIN is proximal nodular scarring (often from infection).
7. IUI vs. IVF-ICSI: IUI still requires patent tubes and decent sperm; IVF-ICSI can bypass blocked tubes and severe sperm counts.
8. OHSS Moderate vs. Severe: Moderate has ascites on ultrasound only; Severe has clinically evident ascites (distended abdomen) and hemoconcentration (Hct >45%).
9. OHSS Severe vs. Critical: Severe has ascites/effusions; Critical adds organ failure (Oliguria, Creatinine >1.6, or Thrombosis).
10. Azoospermia (Obstructive vs. Non-obstructive): Obstructive (e.g., absent vas deferens) has a better prognosis for sperm retrieval than Non-obstructive (e.g., genetic failure).
11. Y-Chromosome Microdeletions: Sperm can be retrieved in AZFb/AZFc deletions, but NOT in AZFa deletions.
12. AMH vs. FSH: AMH is cycle-independent (can be taken anytime); FSH must be taken on Day 2-3 to be accurate.
13. Day 3 vs. Day 5 Embryo Transfer: Day 3 are cleavage-stage (6-8 cells); Day 5 are blastocysts (ready for implantation).
14. PGT-A vs. PGT-M: PGT-A is for chromosomal quantity (e.g., Down Syndrome); PGT-M is for specific single-gene mutations (e.g., Cystic Fibrosis).
15. Intramural Myoma >4 cm decreases pregnancy rates; Submucous Myoma (any size) decreases pregnancy rates and requires removal.
16. Oil-based vs. Water-based HSG contrast: Oil-based potentially increases pregnancy rates but risk granuloma; Water-based is safer and more common.
17. Endometrial Biopsy vs. ERA: Endometrial biopsy for "dating" is obsolete; ERA is a modern genetic analysis used for recurrent implantation failure.
18. Basal Body Temperature (BBT) only confirms that ovulation happened after it occurred; it is not good for timing intercourse in the same cycle.
19. Infertility Workup: A single abnormal semen analysis is not diagnostic; it must be repeated after 4 weeks because sperm takes ~3 months to mature.
20. GIFT vs. ZIFT: GIFT is Gamete transfer (pre-fertilization) into the tube; ZIFT is Zygote transfer (post-fertilization) into the tube. Both are rarely used compared to IVF-ET.

QA

text

Infertility and Assisted Reproductive Technology (ART) Overview

1. What is the definition of Infertility? | Inability to conceive
   After 1 year of unprotected sex (6 months if >35).
2. What are the clinical manifestations of Infertility? (3) | Oligo/amenorrhea,
   Tubal obstruction,
   Endometriosis
3. What is the diagnosis and work-up for Infertility? | Comprehensive History and PE
   Ancillary testing (Semen analysis, HSG).
4. What are the treatment options for Infertility? (3) | Ovulation induction,
   IUI,
   IVF
5. What is the pathogenesis of Male Factor Infertility? | Issues with sperm
   Producton, motility, or morphology issues (25% of cases).
6. What are the clinical findings of Male Factor Infertility? | Oligospermia or azoospermia
   Low sperm count or absence of sperm.
7. What is the primary diagnostic tool for Male Factor Infertility? | Semen Analysis
   Based on WHO 2010 criteria.
8. What are the WHO 2010 criteria for Semen Analysis? (4) | Vol ≥1.5mL,
   Conc ≥15M/mL,
   Motility ≥40%,
   Morph ≥4%
9. What is the management for Male Factor Infertility? | Lifestyle changes, IUI, or IVF-ICSI.
10. What is the pathogenesis of Ovulatory Disorders? | HPO axis dysfunction
    Leading to anovulation (27% of female factors).
11. What are the clinical manifestations of Ovulatory Disorders? | Irregular cycles
    Associated with low midluteal progesterone.
12. What diagnostic tests are used for Ovulatory Disorders? (2) | Serum Progesterone
    Basal Body Temperature (BBT)
13. What is the first-line treatment for Ovulatory Disorders? | Clomiphene Citrate or Letrozole.
14. What are the common Tubal/Uterine Factors in infertility? | Physical blockages
    Structural abnormalities like hydrosalpinx or myomas.
15. How are Tubal/Uterine Factors diagnosed? (2) | HSG and Laparoscopy. |
16. What is the management for Tubal/Uterine Factors? | Tubal surgery,
    Myomectomy, or IVF.
17. Define the pathogenesis of Endometriosis in infertility. | Inflammatory disease
    Affects 40% of infertile women.
18. What are the clinical manifestations of Endometriosis? (3) | Pain,
    Reduced fecundity,
    Mechanical obstruction
19. What is the gold standard for Endometriosis diagnosis? | Laparoscopy
    Provides a visual diagnosis.
20. What is the treatment for infertility caused by Endometriosis? | COS + IUI
    IVF if no pregnancy after 3-6 cycles.
21. What is Ovarian Hyperstimulation Syndrome (OHSS)? | Iatrogenic complication
    Result of gonadotropin therapy.
22. What are clinical signs of OHSS? (3) | Ovarian enlargement,
    Ascites,
    Hemoconcentration
23. How is OHSS managed? | Supportive care
    Fluids, electrolytes, and avoiding HCG trigger.

Definitions & Epidemiology

24. Define Infertility (General definition). | Inability to conceive
    Within 1 year of unprotected sexual contact.
25. When is an Early Infertility evaluation warranted (after 6 months)? (5) | Women >35,
    Oligo/amenorrhea,
    Tubal disease,
    Endometriosis,
    Male factors
26. What is Fecundability? | Monthly pregnancy probability
    Typically approximately 20% in fertile couples.
27. What percentage of infertility is due to Female Infertility factors? | 54% of cases.
28. What are the two most common Female Infertility factors? | Ovulatory (27%) and Tubal (22%).
29. What is Unexplained Infertility? | Normal diagnostic tests
    Occurs in 17-20% of couples.
30. How does Infertility prevalence change for age 30-34? | 1 in 7 couples.
31. How does Infertility prevalence change for age 35-40? | 1 in 5 couples.
32. How does Infertility prevalence change for age 40-44? | 1 in 4 couples.
33. How does age affect pregnancy rates for Azoospermic husbands using donor insemination? | Decreases with age
    73% if <25 years; 55.8% if 36-40 years.
34. What is the most common diagnostic category in women undergoing IVF? | Diminished Ovarian Reserve.

Physiology & Optimal Timing

35. What is the Oocyte lifespan? | Less than 24 hours
    After reaching the ampulla.
36. What is the Sperm lifespan in the oviduct? | Up to 72 hours.
37. What is the Optimal conception time? | Day before ovulation
    Or daily for 3 days at mid-cycle.
38. When does ovulation occur if LH Surge detection (First morning urine) is positive? | Same day of detection.
39. When does ovulation occur if LH Surge detection (Random urine) is positive? | 12 to 24 hours later
    Technically the "suivant" or next day.
40. Name four Conception blockers. | Vaginal lubricants,
    Saliva,
    Cigarette smoking,
    Douching

Ovulation & Ovarian Reserve Assessment

41. What Serum Progesterone value suggests some ovulatory function? | >3-5 ng/mL.
42. What Serum Progesterone value suggests a normal ovulatory cycle? | ≥10 ng/mL.
43. What is the physiological basis for Basal Body Temperature (BBT) testing? | Thermogenic effect of progesterone
    Acting on the hypothalamus.
44. What are the requirements for accurate BBT measurement? | Sublingual temperature
    Immediately after awakening after 6 hours sleep.
45. Why is Endometrial Biopsy no longer indicated for routine workup? | Invasive and subjective
    Formerly used for luteal phase defects.
46. Who should undergo Ovarian Reserve Testing? (4) | Women >35,
    Unexplained infertility,
    Smokers,
    History of ovarian surgery/chemo/radiation
47. What does an FSH level >10 mIU/mL on Day 2 or 3 indicate? | Decreased ovarian reserve.
48. What does an FSH level >20 mIU/mL indicate? | Poor prognosis for pregnancy.
49. What Serum Estradiol (E2) level indicates a poor prognosis early in the cycle? | >70 pg/mL.
50. What is Anti-Müllerian Hormone (AMH) produced by? | Granulosa cells.
51. What AMH level indicates decreased ovarian reserve? | <0.5 ng/mL.
52. What AMH level indicates many follicles are available? | >2 ng/mL.
53. What AMH level predicts menopause within 4-5 years? | 0.05 ng/mL.
54. How is the Antral Follicle Count (AFC) measured? | Transvaginal ultrasound (TVS)
    On cycle day 2 to 4.
55. What Antral Follicle Count (AFC) suggests good ovarian reserve? | 10 or more follicles
    Follicles sized 2-10 mm.

Semen Analysis & Male Evaluation

56. What is the required abstinence period for a Male Infertility workup? | 2-3 days of abstinence.
57. When does Sperm motility begin to decline after ejaculation? | After 2 hours.
58. What is the significance of Sperm morphology? | Reflects production from 3 months prior
    Subjective test using Kruger criteria.
59. What is the Kruger criteria threshold for fertilization ability? | 4% normal forms.
60. What are the WHO 2010 Low normal sperm values? (3) | 15 M/mL concentration,
    39 M/ejaculate total,
    40% motility
61. Why must Unwashed seminal fluid NOT be used in IUI? | Causes severe uterine cramps
    Contains prostaglandins and risk of infection.
62. In what condition is Intrauterine Insemination (IUI) less successful? | Significant oligospermia
    <5 million motile sperm.

Hysterosalpingography (HSG) & Tubal Disease

63. What is the optimal HSG Timing? | 10th day of cycle
    Ensures follicular phase/no pregnancy.
64. What are the HSG Contraindications? (2) | Untreated salpingitis
    Tenderness on pelvic exam.
65. Why is Water-soluble contrast preferred in HSG? | Avoids peritoneal irritation
    Prevents oil-induced granulomas.
66. When is Doxycycline prophylaxis given for HSG? | If hydrosalpinx is visualized
    100 mg BID for 1-2 weeks.
67. How does Hydrosalpinx appear on HSG? | Distal blockage with ballooning
    Sausage-like appearance with no dye spillage.
68. What causes Proximal Tubal Obstruction? | True block (SIN, infection)
    Or cornual spasm (false block).
69. Why is Laparoscopic Salpingectomy recommended before IVF for large hydrosalpinx? | Fluid reduces success rates
    Embryo implantation decreased by 40%.
70. What is the best prognostic factor for pregnancy after Tubal reconstructive surgery? | Tubal wall thickness.
71. How does Tubal Tuberculosis appear radiographically? | Pipe stem configuration.
72. What is the fertility prognosis for women with Pelvic Tuberculosis? | Considered sterile.

Medical Management of Anovulation

73. What is the mechanism of Clomiphene Citrate (CC)? | Selective estrogen receptor antagonist.
74. What is the typical dose and timing for Clomiphene Citrate? | 50-150 mg for 5 days
    Starting on cycle day 3-5.
75. Name four Clomiphene side effects. | Multiple gestations (8%),
    Ovarian cysts,
    Vasomotor flushes,
    Blurring of vision
76. What is the "Stair-step" CC Regimen? | Immediate dose increase
    Used if no follicle develops within the same cycle.
77. What is the mechanism of Letrozole? | Aromatase inhibitor.
78. Why is Letrozole preferred for PCOS patients? | Higher live birth rates
    Lower incidence of multiple pregnancy.
79. What is the role of Metformin in infertility? | Adjunct for obese PCOS
    Insulin-sensitizing biguanide.
80. When are Gonadotropins (FSH/HMG) indicated? | Unresponsive to CC/Letrozole.
81. Why is ultrasound monitoring required for Gonadotropins? | To prevent OHSS.
82. What is the function of HCG (5,000-10,000 IU) in ART? | Trigger for ovulation
    Occurs 36-48 hours after administration.
83. What is the treatment for anovulation due to Hyperprolactinemia? | Dopamine Agonists.

Ovarian Hyperstimulation Syndrome (OHSS)

84. What is the OHSS Pathogenesis? | High E2 and VEGF secretion
    Leads to vascular permeability/fluid shifts.
85. Define OHSS Mild. | Ovarian enlargement ≤5 cm
    Accompanied by abdominal discomfort.
86. Define OHSS Moderate. | Ovarian enlargement 6-10 cm
    Nausea and mild ascites (on ultrasound).
87. Define OHSS Severe. | Clinically evident ascites/hydrothorax
    Hematocrit >45% and high WBC.
88. Define OHSS Critical. (4) | Oliguria,
    Creatinine >1.6 mg/dL,
    Thrombosis,
    DIC
89. How is OHSS prevented in ART? (3) | GnRH agonist trigger,
    Lowering gonadotropin doses,
    "Coasting"

In-Vitro Fertilization (IVF) Specifics

90. List four IVF Indications. | Blocked tubes,
    Severe male factor,
    Advanced maternal age,
    Failed IUI
91. What is Intracytoplasmic Sperm Injection (ICSI)? | Single sperm injection
    Directly into a mature oocyte.
92. When is ICSI preferred? (3) | Male factor,
    Failed fertilization,
    Frozen oocytes
93. When is Oocyte Harvesting performed? | 34-36 hours after HCG trigger.
94. What are the ultrasound requirements for Oocyte Harvesting? | ≥3 mature follicles
    Size ≥18 mm.
95. Compare Embryo Transfer (Day 3 vs Day 5). | Day 5 (Blastocysts)
    Higher implantation and pregnancy rates.
96. What is the risk associated with Assisted Hatching (AH)? | Monozygotic twinning.
97. What is Elective Single Embryo Transfer (eSET)? | Recommended for women <35
    To minimize high-risk multifetal pregnancies.
98. What is the advantage of In-Vitro Maturation (IVM) in PCOS? | Eliminates OHSS risk
    Harvests and matures immature eggs outside the body.
99. What does Frozen Embryo Transfer (FET) require? | Estrogen therapy
    And progesterone 4-6 days before transfer.
100. Define Recurrent Implantation Failure. | 3 failed good embryo transfers
     Or 2 failed euploid blastocyst transfers.
101. What test is used for Recurrent Implantation Failure? | Endometrial Receptivity Analysis (ERA).

Genetic Testing & Fertility Preservation

102. What is PGT-A? | Testing for aneuploidy
     Abnormal chromosome number.
103. What is PGT-M? | Testing for monogenic diseases
     e.g., Cystic Fibrosis, Tay-Sachs.
104. What is the preferred method for PGT Biopsy? | Trophectoderm Biopsy
     Performed on Day 5 or 6 blastocysts.
105. What is Social Freezing? | Oocyte cryopreservation
     To delay childbearing/delay age effect.
106. Why is a GnRH agonist used during chemotherapy? | To protect ovaries
     Suppresses HPG axis and reduces blood flow.
107. When is Ovarian tissue cryopreservation contraindicated? | Leukemias
     Risk of malignant cell re-seeding.

Differentiating Similar Entities & Exam High-Yield Points

108. Compare Fecundability vs Fecundity. | Fecundability: Monthly pregnancy probability (20%)
     Fecundity: Monthly live birth probability.
109. Compare LH Test (First morning vs Random urine) timing. | First morning: Ovulation today
     Random: Ovulation tomorrow (12-24h).
110. Compare Clomiphene Citrate vs Letrozole mechanism. | CC: Estrogen receptor antagonist
     Letrozole: Aromatase inhibitor.
111. Compare Letrozole vs Clomiphene in PCOS. | Letrozole is superior
     Higher live birth rates.
112. Compare Serum Progesterone levels (>3 vs ≥10 ng/mL). | >3: Confirms ovulation
     ≥10: Threshold for healthy conception.
113. Compare Hydrosalpinx vs SIN location. | Hydrosalpinx: Distal ballooning
     SIN: Proximal nodular scarring.
114. Compare IUI vs IVF-ICSI requirements. | IUI: Patent tubes/decent sperm
     IVF-ICSI: Can bypass blocked tubes/severe male factor.
115. Compare OHSS Moderate vs Severe (Ascites). | Moderate: Ascites on U/S only
     Severe: Clinically evident ascites.
116. Contrast OHSS Severe vs Critical. | Critical adds organ failure
     Creatinine >1.6 or thrombosis.
117. Compare Azoospermia (Obstructive vs Non-obstructive) prognosis. | Obstructive has better sperm retrieval prognosis
     e.g., absent vas deferens vs genetic failure.
118. Can sperm be retrieved in Y-Chromosome Microdeletions? | Yes in AZFb/AZFc
     No in AZFa deletions.
119. Compare AMH vs FSH cycle timing. | AMH: Cycle-independent
     FSH: Must be Day 2-3.
120. Compare Day 3 vs Day 5 Embryos. | Day 3: Cleavage-stage (6-8 cells)
     Day 5: Blastocysts.
121. Compare PGT-A vs PGT-M targets. | PGT-A: Chromosomal quantity
     PGT-M: Specific single-gene mutations.
122. Compare Intramural vs Submucous Myoma. | Intramural (>4cm): Decreases rate
     Submucous (any size): Decreases rate/requires removal.
123. Compare Oil-based vs Water-based HSG contrast. | Oil: Potential pregnancy increase/risk granuloma
     Water: Safer and more common.
124. Compare Endometrial Biopsy vs ERA. | Biopsy: Obsolete for dating
     ERA: Modern genetic analysis for implantation failure.
125. Why is Basal Body Temperature (BBT) bad for timing? | Only confirms ovulation occurred
     Retroactive confirmation only.
126. Why is one Semen analysis result not diagnostic? | Sperm takes 3 months to mature
     Must repeat after 4 weeks.
127. Compare GIFT vs ZIFT. | GIFT: Gametes into tube
     ZIFT: Zygote into tube.

2

Summary

text

I. Overview of Immunologic Response

• Pattern Recognition Receptors (PRRs) are germline-encoded receptors on effector cells that detect Pathogen-Associated Molecular Patterns (PAMPs) on microbes to trigger inflammation.
• Toll-Like Receptors (TLRs) are a type of PRR that stimulates type 1 interferon (IFN), which possesses antimicrobial, antiviral, and anticancer properties.
• Natural Killer (NK) Cells are very important in cancer management; they directly kill infected or tumor cells that lack MHC class I molecules.
• Complement System activation leads to C3 cleavage and the formation of membrane pores via C6, C7, C8, and C9 proteins, resulting in cell lysis.
• Humoral Immunity (B cells) involves B cells originating in the bone marrow and differentiating into plasma cells to secrete antibodies (immunoglobulins).
• Antibody Structure consists of two heavy and two light chains; the Variable (V) region provides antigen specificity, while the Constant (C) region binds to phagocytes.
• IgM is the first antibody produced in an immune response and is a potent activator of the complement system.
• IgG serves in the later immune response, provides neonatal immunity via placental transfer, and coats antigens for phagocytosis (opsonization).
• Cellular Immunity (T cells) requires direct cell-to-cell contact and recognizes peptide antigens only when presented on MHC molecules.
• Class I MHC is found on all nucleated cells and activates CD8+ Cytotoxic T Lymphocytes (CTLs) to destroy tumor or infected cells.
• Class II MHC is found only on Antigen-Presenting Cells (APCs) and activates CD4+ Helper T cells.
• Regulatory T Cells (Tregs) are CD4+ T cells that suppress the immune response; in cancer, they may prevent the immune system from recognizing tumor "self-antigens."
• Th1 Cells secrete IL-2 and IFN-γ to promote cell-mediated inflammatory responses, while Th2 Cells secrete IL-4, IL-5, IL-6, and IL-10 to promote antibody production.

II. Cancer Immunity Cycle & Immunotypes

• The Cancer Immunity Cycle is a 7-step iterative process: 1) Release of antigens, 2) Antigen presentation, 3) Priming/Activation, 4) Trafficking to tumors, 5) Infiltration, 6) Recognition, and 7) Killing of cancer cells.
• Immune Desert immunotype is characterized by a complete paucity of immune cells within the tumor microenvironment (TME).
• Immune Excluded immunotype occurs when T cells are present in the stroma but are prevented from migrating into the actual cancer cell nests by inhibitory barriers.
• Inflamed Tumors contain stimulatory immune cells and tumor-infiltrating lymphocytes (TILs), which increase functional killing of cancer cells.
• Stimulatory Factors (Green) in the cancer cycle include IFN-α, IL-2, and TLR agonists; their presence is used for monitoring and prognostication.
• Inhibitory Factors (Red) such as PD-L1, CTLA-4, and VEGF help cancer cells evade the immune response and are targets for immunotherapy medications.
• CAR-T Therapy involves genetically modifying a patient's T cells to express Chimeric Antigen Receptors targeting specific tumor antigens like mesothelin or MUC16.

III. Cytokines in Oncology

• M1 Macrophages secrete stimulatory cytokines (IL-12, TNF-α) to promote immunity against tumors.
• M2 Macrophages produce immunosuppressive factors (VEGF, IL-10, PGE2) that assist established tumors in growing and evading the immune system.
• Type I Interferons (IFN-α/β) are stimulated by TLRs to inhibit viral replication and increase Class I MHC expression.
• Type II Interferon (IFN-γ) is produced by T cells/NK cells to activate macrophages and promote the Th1 (cellular immunity) pathway.
• TGF-β inhibits T-cell proliferation and is a major contributor to tumor immune evasion.
• Chemokines are small proteins that regulate leukocyte infiltration, promote angiogenesis, and control site-specific metastasis.

IV. Molecular Oncology: Oncogenes & Tumor Suppressors

• Oncogenes are mutated derivatives of normal genes that result in a GAIN OF FUNCTION; alteration mechanisms include gene amplification, translocation, and overexpression.
• Tumor Suppressor Genes control cell growth and proliferation; cancer develops following a LOSS OF FUNCTION (inactivation of both alleles).
• p53 is the "gate keeper of the genome" and the most common deregulated tumor suppressor; located on chromosome 17, it triggers apoptosis (via BAX, bcl-2) in response to DNA damage.
• PTEN (Phosphatase and tensin homologue) is a tumor suppressor on chromosome 10 that is mutated in 50% of endometrioid endometrial cancers and 20% of endometrial hyperplasias.
• Retinoblastoma (Rb) Gene regulates G1 phase arrest; its inactivation follows Knudson’s "two-hit" theory (one inherited mutation, one somatic).
• HPV E6 Oncoprotein (types 16/18) targets p53 for degradation, while HPV E7 Oncoprotein binds to Rb to upregulate cell proliferation in cervical cancer.
• Somatic Mutations occur after conception in any body cell except germ cells and are not passed to offspring.
• Germline Mutations occur in reproductive cells (egg/sperm) and are incorporated into the DNA of every cell in the offspring.

V. BRCA Genes & PARP Inhibitors

• BRCA1 Gene is located on chromosome 17q21; mutation carriers have a 40-50% risk of ovarian cancer by age 70.
• BRCA2 Gene is located on chromosome 13q12.3; carries a 20-25% ovarian cancer risk and is linked to male breast, pancreatic, and biliary cancers.
• BRCA Genetic Testing is indicated for nonmucinous epithelial ovarian cancer at any age, or breast cancer before age 50 with a strong family history.
• PARP Inhibitors (e.g., Olaparib, Rucaparib, Niraparib) kill BRCA-deficient cells by causing an accumulation of DNA double-strand breaks that the cells cannot repair.
• The SOLO-1 Trial demonstrated that Olaparib maintenance therapy reduces disease progression or death by 70% in BRCA-mutated ovarian cancer.

VI. DNA Mismatch Repair (MMR) & Lynch Syndrome

• Mismatch Repair (MMR) Deficiency leads to Microsatellite Instability (MSI); it is found in over 30% of endometrial cancers.
• The MMR Repair Pathway involves the MutS complex (recognition), MutL (excision), and re-synthesis of DNA strands.
• Lynch Syndrome (HNPCC) is an autosomal dominant syndrome caused by germline mutations in MMR genes (MSH2, MLH1, MSH6, PMS2) predisposing to colorectal and endometrial cancers.
• MSH2 (Chr 2) and MLH1 (Chr 3) are the most common mutations in Lynch Syndrome.
• The Amsterdam Criteria II for Lynch diagnosis (the "3-2-1" rule): 3 relatives with HNPCC cancer (one being a 1st-degree relative of others), 2 successive generations, and 1 diagnosed before age 50.
• The Bethesda Guidelines are more sensitive than Amsterdam for identifying patients needing MSI testing, including those with colorectal/uterine cancer diagnosed under age 50.
• Immunotherapy (e.g., Dostarlimab) is highly effective for dMMR/MSI-H recurrent or advanced endometrial cancer.

VII. Recent Advances & Local (Philippine) Context

• CloneSeq-SV is a new technique used in high-grade serous ovarian cancer (HGSOC) to track clonal evolution and drug resistance markers (e.g., CCNE1, MYC) using cell-free DNA.
• High-Grade Serous Ovarian Cancer (HGSOC) drug resistance is often pre-existing at diagnosis, leading to clonal selection during treatment.
• AI-Based Biomarkers use deep learning to quantify TILs or PD-L1/HER2 expression from digitized pathology slides.
• In the Philippines, cervical cancer is the most common gynecologic malignancy, and research is currently focusing on PD-L1 expression for immunotherapy.
• Neoadjuvant Olaparib is being studied for advanced BRCA-mutated ovarian cancer patients who are ineligible for primary surgery.
• Philippine Gynecologic Oncology Research Group (PGOG) conducts multi-center trials to improve local data on gynecologic cancers.

VIII. Comparison of Similar Entities for Exams

1. Innate vs. Adaptive Immunity: Innate is rapid and non-specific with no memory; Adaptive is slow-onset, highly specific, and possesses immunologic memory.
2. MHC Class I vs. MHC Class II: MHC I is on all nucleated cells (presents to CD8+ T cells); MHC II is only on APCs (presents to CD4+ T cells).
3. Oncogenes vs. Tumor Suppressor Genes: Oncogenes result from a Gain of Function (one allele mutated); Tumor Suppressors result from a Loss of Function (both alleles must be inactivated).
4. BRCA1 vs. BRCA2: BRCA1 is on Chr 17 (higher ovarian risk ~50%); BRCA2 is on Chr 13 (lower ovarian risk ~20% and associated with male breast/pancreatic cancer).
5. Amsterdam I vs. Amsterdam II Criteria: Amsterdam I only included colorectal cancer; Amsterdam II was revised to include extracolonic HNPCC cancers (endometrial, small bowel, ureter, etc.).
6. Bethesda vs. Amsterdam II Criteria: Bethesda is more sensitive (catches more potential Lynch cases); Amsterdam II is more specific (higher certainty if criteria are met).
7. M1 vs. M2 Macrophages: M1 promotes tumor killing (pro-inflammatory); M2 promotes tumor growth/evasion (immunosuppressive).
8. Somatic vs. Germline Mutation: Somatic is not heritable (occurs after conception); Germline is heritable (present in reproductive cells and every cell of offspring).
9. Th1 vs. Th2 Cells: Th1 promotes cell-mediated immunity (IFN-γ); Th2 promotes humoral/antibody immunity (IL-4).
10. IgG vs. IgM: IgG crosses the placenta and is part of the late/memory response; IgM is the first produced and stays in the vascular space (pentamer).
11. HPV E6 vs. HPV E7: E6 degrades p53; E7 binds/inactivates Rb.
12. Immune Desert vs. Immune Excluded: In "Desert," immune cells are absent from the TME; in "Excluded," immune cells exist in the stroma but cannot penetrate the tumor nest.
13. G-CSF vs. Erythropoietin (EPO): G-CSF stimulates neutrophil production (innate); EPO stimulates red blood cell production.
14. Cytotoxic T-cells (CTLs) vs. Natural Killer (NK) Cells: CTLs require MHC presentation to recognize targets; NK cells kill targets specifically because they lack MHC I expression.
15. MSI-H vs. dMMR: MSI-H (High Microsatellite Instability) is the phenotype/effect; dMMR (deficient Mismatch Repair) is the mechanism/cause.

QA

code

I. Overview of Immunologic Response

1. Describe the specificity of Innate Immunity. | Non-specific; recognizes broad patterns (PAMPs).
2. Describe the specificity of Adaptive Immunity. | Highly specific to unique pathogens/antigens.
3. Does Innate Immunity possess immunologic memory? | No immunologic memory.
4. How does the response of Adaptive Immunity change on re-exposure? | Response increases with repeated exposure.
5. List the components of Innate Immunity. (6) | 1) Epithelial barriers
   2) Macrophages
   3) NK cells
   4) Neutrophils
   5) Dendritic cells
   6) Complement
6. List the components of Adaptive Immunity. (2) | 1) T cells (Cell-mediated)
   2) B cells (Humoral)
7. Compare the response time of Innate vs. Adaptive Immunity. | Innate is rapid/first line; Adaptive is slower initially.
8. Define Pattern Recognition Receptors (PRRs). | Germline-encoded receptors detecting PAMPs.
9. What is the role of Pattern Recognition Receptors (PRRs) in the immune response? | Trigger inflammation.
10. What are Pathogen-Associated Molecular Patterns (PAMPs)? | Broad patterns on microbes detected by PRRs.
11. What type of PRR stimulates Type 1 Interferon (IFN)? | Toll-Like Receptors (TLRs).
12. List the three properties of Type 1 Interferon (IFN). | Antimicrobial, antiviral, and anticancer.
13. Why are Natural Killer (NK) Cells important in cancer management? | Kill cells lacking MHC class I molecules.
14. Which cells do Natural Killer (NK) Cells directly kill? | Infected or tumor cells.
15. What event occurs first in the Complement System activation? | C3 cleavage.
16. Which proteins form membrane pores in the Complement System? | C6, C7, C8, and C9.
17. What is the final result of membrane pore formation by the Complement System? | Cell lysis.
18. Where do B cells in Humoral Immunity originate? | Bone marrow.
19. What do B cells differentiate into to secrete antibodies in Humoral Immunity? | Plasma cells.
20. Describe the basic Antibody Structure. | Two heavy and two light chains.
21. What is the function of the Variable (V) region of an antibody? | Provides antigen specificity.
22. What is the function of the Constant (C) region of an antibody? | Binds to phagocytes.
23. Which antibody is the first produced in an Immune Response? | IgM.
24. What system is IgM a potent activator of? | Complement system.
25. What is the role of IgG in the immune response? | Serves in the later immune response.
26. How does IgG provide neonatal immunity? | Placental transfer.
27. Define Opsonization by IgG. | Coating antigens for phagocytosis.
28. What does Cellular Immunity (T cells) require for activation? | Direct cell-to-cell contact.
29. When do T cells recognize Peptide Antigens? | Only when presented on MHC molecules.
30. Where is Class I MHC found? | All nucleated cells.
31. Which cells are activated by Class I MHC? | CD8+ Cytotoxic T Lymphocytes (CTLs).
32. What is the target of CD8+ Cytotoxic T Lymphocytes (CTLs)? | Tumor or infected cells.
33. Where is Class II MHC found? | Antigen-Presenting Cells (APCs).
34. Which cells are activated by Class II MHC? | CD4+ Helper T cells.
35. What is the function of Regulatory T Cells (Tregs)? | Suppress the immune response.
36. Identify the markers for Regulatory T Cells (Tregs). | CD4+.
37. How do Regulatory T Cells (Tregs) assist cancer cells? | Prevent recognition of tumor "self-antigens."
38. What cytokines are secreted by Th1 Cells? (2) | IL-2 and IFN-γ.
39. What type of response is promoted by Th1 Cells? | Cell-mediated inflammatory responses.
40. What cytokines are secreted by Th2 Cells? (4) | IL-4, IL-5, IL-6, and IL-10.
41. What is the primary function of Th2 Cells? | Promote antibody production.

II. Cancer Immunity Cycle & Immunotypes

42. How many steps are in the Cancer Immunity Cycle? | 7 steps.
43. List the first three steps of the Cancer Immunity Cycle. | 1) Release of antigens
    2) Antigen presentation
    3) Priming/Activation
44. List the last four steps of the Cancer Immunity Cycle. | 4) Trafficking
    5) Infiltration
    6) Recognition
    7) Killing
45. Describe the Immune Desert immunotype. | Complete paucity of immune cells.
46. Where are T cells located in the Immune Excluded immunotype? | In the stroma.
47. What prevents T cell migration in Immune Excluded tumors? | Inhibitory barriers.
48. What are the components of Inflamed Tumors? | Stimulatory immune cells and TILs.
49. What is the effect of Tumor-Infiltrating Lymphocytes (TILs) in inflamed tumors? | Increase functional killing of cancer cells.
50. List the Stimulatory Factors (Green) in the cancer cycle. (3) | IFN-α, IL-2, and TLR agonists.
51. What is the clinical use of Stimulatory Factors? | Monitoring and prognostication.
52. List Inhibitory Factors (Red) in cancer immunity. (3) | PD-L1, CTLA-4, and VEGF.
53. What is the purpose of Inhibitory Factors for a tumor? | Evade the immune response.
54. Define CAR-T Therapy. | Genetically modifying T cells with Chimeric Antigen Receptors.
55. Name two specific tumor antigens targeted by CAR-T Therapy. | Mesothelin or MUC16.

III. Cytokines in Oncology

56. Which cytokines mediate Innate Immunity? (5) | IL-1, IL-12, IL-18, IL-23, TNF, IFN.
57. Which cytokine links Innate and Adaptive Immunity? | IL-12.
58. List cytokines associated with Adaptive Immunity. (6) | IL-2, IL-4, IL-5, IL-13, TGF-β, IFN-γ.
59. What is the function of IL-2 in adaptive immunity? | Clonal expansion of T cells.
60. Which cytokine aids Tumor Evasion in adaptive immunity? | TGF-β.
61. List cytokines involved in Hematopoiesis. (4) | G-CSF, GM-CSF, IL-3, Erythropoietin (EPO).
62. What is the clinical use of G-CSF? | Manage chemo-induced neutropenia.
63. What do M1 Macrophages secrete? | IL-12 and TNF-α.
64. What is the role of M1 Macrophages? | Promote immunity against tumors.
65. What do M2 Macrophages produce? (3) | VEGF, IL-10, PGE2.
66. How do M2 Macrophages assist tumors? | Growth and immune evasion.
67. What stimulates Type I Interferons (IFN-α/β)? | Toll-Like Receptors (TLRs).
68. What are the two main functions of Type I Interferons? | 1) Inhibit viral replication
    2) Increase Class I MHC.
69. Which cells produce Type II Interferon (IFN-γ)? | T cells and NK cells.
70. What is the role of Type II Interferon (IFN-γ)? | Activate macrophages and promote Th1.
71. How does TGF-β impact T-cells? | Inhibits T-cell proliferation.
72. Define the role of Chemokines in oncology. (3) | 1) Leukocyte infiltration
    2) Angiogenesis
    3) Metastasis.

IV. Molecular Oncology: Oncogenes & Tumor Suppressors

73. Define Oncogenes. | Mutated genes causing Gain of Function.
74. List mechanisms of Oncogene alteration. (3) | Gene amplification, translocation, overexpression.
75. Define Tumor Suppressor Genes. | Genes that control cell growth.
76. What mechanism causes cancer via Tumor Suppressor Genes? | Loss of Function (inactivation of both alleles).
77. What is the nickname for p53? | Gate keeper of the genome.
78. Where is the p53 gene located? | Chromosome 17.
79. How does p53 trigger apoptosis? | Via BAX and bcl-2.
80. Where is PTEN located? | Chromosome 10.
81. In what percentage of Endometrioid Endometrial Cancers is PTEN mutated? | 50%.
82. What does the Retinoblastoma (Rb) Gene regulate? | G1 phase arrest.
83. Define Knudson’s "two-hit" theory for Rb. | One inherited mutation, one somatic.
84. What is the target of HPV E6 Oncoprotein? | p53 degradation.
85. What is the target of HPV E7 Oncoprotein? | Binding/inactivation of Rb.
86. Define Somatic Mutations heritability. | Not passed to offspring.
87. Where do Germline Mutations occur? | Reproductive cells (egg/sperm).
88. Which cells contain the mutation in Germline Mutations? | Every cell in the offspring.

V. BRCA Genes & PARP Inhibitors

89. Where is the BRCA1 Gene located? | Chromosome 17q21.
90. What is the ovarian cancer risk for BRCA1 carriers by age 70? | 40-50%.
91. Where is the BRCA2 Gene located? | Chromosome 13q12.3.
92. What is the ovarian cancer risk for BRCA2 carriers? | 20-25%.
93. List non-breast/ovarian cancers linked to BRCA2. (3) | Male breast, pancreatic, biliary.
94. When is BRCA Genetic Testing indicated for ovarian cancer? | Nonmucinous epithelial at any age.
95. When is BRCA Genetic Testing indicated for breast cancer? | Before age 50 with family history.
96. Provide three examples of PARP Inhibitors. | Olaparib, Rucaparib, Niraparib.
97. How do PARP Inhibitors kill BRCA-deficient cells? | Accumulation of DNA double-strand breaks.
98. What was the outcome of the SOLO-1 Trial? | Olaparib reduced progression/death by 70%.

VI. DNA Mismatch Repair (MMR) & Lynch Syndrome

99. What does Mismatch Repair (MMR) Deficiency lead to? | Microsatellite Instability (MSI).
100. Percentage of Endometrial Cancers with MMR deficiency? | Over 30%.
101. Match MutS and MutL to their functions. | MutS (recognition); MutL (excision).
102. What is Lynch Syndrome (HNPCC)? | Autosomal dominant germline MMR mutation.
103. List the four MMR Genes mutated in Lynch Syndrome. | MSH2, MLH1, MSH6, PMS2.
104. Which two mutations are most common in Lynch Syndrome? | MSH2 and MLH1.
105. State the "3-2-1" rule of Amsterdam Criteria II. | 3 relatives, 2 generations, 1 diagnosed <50.
106. Explain the "3" in the Amsterdam Criteria II. | 3 relatives with HNPCC cancer.
107. What is the advantage of Bethesda Guidelines over Amsterdam? | More sensitive for identifying MSI testing.
108. Which drug is used for dMMR/MSI-H recurrent endometrial cancer? | Dostarlimab.

VII. Recent Advances & Local (Philippine) Context

109. What is CloneSeq-SV used for? | Track clonal evolution using cell-free DNA.
110. List two drug resistance markers tracked by CloneSeq-SV. | CCNE1 and MYC.
111. When is drug resistance typically present in HGSOC? | Pre-existing at diagnosis.
112. How do AI-Based Biomarkers assist pathology? | Quantify TILs or PD-L1/HER2 expression.
113. What is the most common gynecologic malignancy in the Philippines? | Cervical cancer.
114. What is the research focus for Philippine cervical cancer? | PD-L1 expression.
115. Who is eligible for Neoadjuvant Olaparib study? | Advanced BRCA-mutated, surgical ineligible.
116. What is the PGOG? | Philippine Gynecologic Oncology Research Group.

VIII. Comparison of Similar Entities

117. Compare Innate vs. Adaptive memory. | Innate: No memory; Adaptive: Immunologic memory.
118. Compare MHC Class I vs. Class II distribution. | Class I: All nucleated cells; Class II: APCs.
119. Compare MHC Class I vs. Class II activation. | Class I: CD8+ T cells; Class II: CD4+ T cells.
120. Compare Oncogenes vs. Tumor Suppressor Genes mechanism. | Oncogenes: Gain of Function; Tumor Suppressors: Loss of Function.
121. Compare BRCA1 vs. BRCA2 chromosome locations. | BRCA1: Chr 17; BRCA2: Chr 13.
122. Contrast Amsterdam I vs. Amsterdam II. | II includes extracolonic cancers (endometrial, etc).
123. Contrast Bethesda vs. Amsterdam II. | Bethesda is more sensitive; Amsterdam is more specific.
124. Contrast M1 vs. M2 Macrophages. | M1: Tumor killing; M2: Tumor growth/evasion.
125. Contrast Somatic vs. Germline Mutation heritability. | Somatic: Not heritable; Germline: Heritable.
126. Contrast Th1 vs. Th2 Cells immunity type. | Th1: Cell-mediated (IFN-γ); Th2: Humoral (IL-4).
127. Contrast IgG vs. IgM placentation. | IgG: Crosses placenta; IgM: Does not cross.
128. Contrast HPV E6 vs. E7 targets. | E6: p53; E7: Rb.
129. Contrast Immune Desert vs. Excluded. | Desert: Absent cells; Excluded: Stroma-only cells.
130. Contrast G-CSF vs. EPO targets. | G-CSF: Neutrophils; EPO: Red blood cells.
131. Contrast CTLs vs. NK Cells recognition. | CTLs require MHC; NK cells kill if MHC is lacking.
132. Compare MSI-H vs. dMMR relationship. | MSI-H: Phenotype/effect; dMMR: Mechanism/cause.

3

Summary

text

I. Principles of Radiation Therapy & Physics

• Electromagnetic radiation is a form of energy with no mass or charge that travels at the speed of light.
• The inverse square law states that radiation energy per unit area is inversely proportional to the square of the distance from the source (1/r²).
• The fractional cell kill principle establishes that each delivered radiation dose kills a constant fraction (not a constant number) of tumor cells.
• Therapeutic goal of radiation is to achieve maximum local tumor control while minimizing normal tissue damage and adverse symptoms.
• Radiation resistance is associated with cellular hypoxia, nutritional deficiency, or enhanced cell-mediated repair of DNA damage.
• Photons (X-rays and Gamma rays) are the most common source of radiation used in the treatment of gynecologic malignancies.
• Gamma rays are photons that originate from the atomic nucleus.
• X-rays are photons that originate from extranuclear (atomic orbital) interactions.
• Bremsstrahlung ("braking radiation") is produced when accelerated electrons hit a high atomic number (Z) target, generating photons of various energies.
• Particulate radiation includes alpha particles, protons, neutrons, and electrons, which randomly ionize atoms to produce tissue effects.
• Protons demonstrate a characteristic "Bragg peak," where the peak dose is deposited at the end of the particle's range, sparing initial tissue.

II. Photon Interactions & Radiobiology

• Coherent Scattering occurs at low energies (<10 keV) and results in no energy loss or radiobiologic effect.
• Photoelectric Effect (10 to 60 keV) involves total photon absorption and electron ejection; it is responsible for high tissue-bone contrast in imaging.
• Compton Effect (60 keV to 10 MeV) is the predominant interaction in human tissue (90% water) and is the most important interaction at therapeutic energies (4 to 18 MeV).
• Pair Production requires photon energy >1.022 MeV and results in the formation of an electron-positron pair; it is the basis of PET imaging.
• Indirect DNA damage accounts for two-thirds of radiation-induced damage and is caused by the formation of highly reactive hydroxyl radicals (OH) from water.
• Sublethal DNA damage repair occurs more effectively in normal cells than in malignant cells, which often have faulty genomic monitors.
• Intracellular molecular oxygen is essential for "fixing" DNA damage caused by free radicals; tumor hypoxia therefore leads to radiation resistance.
• High-LET (Linear Energy Transfer) radiation, such as neutrons or alpha particles, is densely ionizing and causes cell death independent of tissue oxygenation.
• Amifostine is a radioprotector that scavenges free radicals; it can reduce cisplatin-induced renal toxicity in ovarian cancer.
• Mitotic death is the most common form of radiation-induced cell death, occurring after the cell attempts to divide.

III. Tissue Sensitivity & The Cell Cycle

• M phase (Mitosis) is the most radiosensitive phase of the cell cycle because DNA is tightly packaged.
• S phase (DNA Synthesis) is the most radioresistant phase of the cell cycle due to the presence of repair enzymes used during replication.
• Radiosensitivity is highest in rapidly proliferating cells.
• G1 and G2 phases are more radiosensitive than the S phase but less so than the M phase.
• Hemoglobin levels (>10 mg/dL) are associated with improved tumor oxygenation and superior outcomes in cervical cancer radiation therapy.

IV. Radiation Techniques: Teletherapy & Brachytherapy

• Teletherapy (External Beam) delivers radiation from a source located at a distance from the patient, typically using linear accelerators.
• Intensity-modulated radiotherapy (IMRT) allows the high-dose radiation region to be conformed precisely to the tumor volume, sparing normal tissues like the small bowel.
• Isodose curves connect points in tissue receiving equivalent doses; higher-energy beams (e.g., 22-MeV) penetrate deeper and spare the skin surface.
• Brachytherapy (Internal) involves placing radioactive sources directly within or near the tumor.
• Intracavitary therapy for cervical cancer typically uses the Fletcher-Suit applicator (tandem and ovoids) to deliver dose to the cervix and paracervical tissues.
• High-dose rate (HDR) brachytherapy is performed on an outpatient basis over 3 to 5 hours, usually repeated 3 to 6 times.
• Low-dose rate (LDR) brachytherapy requires a shielded hospital room, bed rest, and prolonged analgesia as the source remains in place for an extended period.
• Cesium-137 (137Cs) is a commonly used radioisotope in gynecologic brachytherapy with a half-life of 30 years.
• Iridium-192 (192Ir) has a half-life of 73.8 days and is frequently used in modern brachytherapy units.

V. Radiation Complications

• Acute radiation effects occur within days to weeks and affect rapidly dividing tissues like skin, intestinal mucosa, and bone marrow.
• Late radiation effects occur months to years later and are caused by vascular damage and connective tissue loss (e.g., fibrosis, fistulas).
• Radiation cystitis presents as dysuria and frequency; it is managed with analgesics like Phenazopyridine.
• Sigmoiditis or enteritis caused by radiation leads to diarrhea, cramping, and malabsorption; management includes a low-roughage diet and antispasmodics.
• Fistulas (vesicovaginal or rectovaginal) typically occur 6 to 24 months post-treatment and often require surgical intervention.
• Radiation recall dermatitis is a skin reaction that occurs when certain chemotherapy agents (e.g., Dactinomycin) are given after previous radiation.

VI. Chemotherapy Principles & Management

• Standard of care for advanced ovarian cancer is six cycles of a taxane-platinum combination (e.g., Paclitaxel + Carboplatin).
• Neoadjuvant chemotherapy is given before surgery to reduce tumor size and improve the likelihood of optimal debulking.
• Maintenance therapy is used to prolong stable disease after the initial primary treatment.
• Myelosuppression is the most common serious toxicity of chemotherapy; it is managed with Granulocyte colony-stimulating factor (G-CSF).
• Body Surface Area (BSA) is the standard metric used to calculate most chemotherapy doses.
• RECIST criteria provide a standardized method for measuring tumor response to treatment via imaging.
• Platinum resistance is defined as tumor recurrence or progression within less than 6 months of completing platinum-based therapy.
• Platinum sensitivity is defined as a disease-free interval of more than 6 months after treatment.

VII. Chemotherapeutic Agents: Details & Toxicity

VIII. PARP Inhibitors & Hormones

• PARP Inhibitors utilize "synthetic lethality" to kill cancer cells that already have deficient DNA repair (e.g., BRCA mutations).
• Olaparib was the first PARP inhibitor approved for BRCA-positive recurrent ovarian cancer.
• Niraparib has shown benefits as consolidation therapy regardless of BRCA status.
• Rucaparib is indicated for platinum-sensitive recurrence after failure of ≥2 lines of chemotherapy.
• Hormonal therapy using Progestins (e.g., Megestrol) is most effective against well-differentiated endometrial carcinomas.

IX. Clinical Trials & Performance Status

• Phase I trials primarily evaluate the safety, toxicity, and maximum tolerated dose of a new drug.
• Phase II trials focus on the therapeutic effectiveness of a drug against a specific tumor type.
• Phase III trials compare a new treatment directly against the current standard of care.
• Karnofsky Performance Status measures a patient's functional condition; a score ≤50 indicates a poor candidate for clinical trials.

X. Pregnancy & Radiation (Williams)

• Fetal radiation exposure may cause malformations, growth restriction, or carcinogenesis depending on dose and gestational age.
• Week 8 to 15 of gestation is the period of highest risk for radiation-induced intellectual disability (threshold ~0.06 Gy).
• Organogenesis (Weeks 2–8) is the period where radiation exposure is most likely to cause structural congenital malformations (threshold 0.1–0.2 Gy).
• Radiotherapy to the maternal abdomen is contraindicated after 25 weeks of gestation.
• Supradiaphragmatic radiotherapy (e.g., for head and neck cancer) can be used during pregnancy if the fetus is shielded.

XI. Comparison of Similar Entities

• Cisplatin vs. Carboplatin: Cisplatin is more nephrotoxic and emetogenic; Carboplatin is more myelosuppressive (thrombocytopenia).
• Teletherapy vs. Brachytherapy: Teletherapy uses an external source at a distance; Brachytherapy uses an internal source placed within or near the tumor.
• Low-LET vs. High-LET: Low-LET (photons) requires oxygen to fix damage; High-LET (alpha/neutrons) kills cells regardless of oxygen presence.
• S-phase vs. M-phase: S-phase is the most radioresistant part of the cell cycle; M-phase is the most radiosensitive.
• Acute vs. Late effects: Acute effects involve rapidly dividing cells (skin/mucosa); Late effects involve slow-renewing tissues (fibrosis/fistula).
• Direct vs. Indirect Action: Direct action is the photon hitting DNA; Indirect action is damage via hydroxyl radicals from water.
• Platinum-sensitive vs. Resistant: Sensitive relapses >6 months after treatment; Resistant relapses <6 months after treatment.
• Paclitaxel vs. Docetaxel: Paclitaxel is derived from Pacific Yew and causes more hypersensitivity; Docetaxel is from English Yew and is more neutropenic.
• Olaparib vs. Niraparib: Olaparib is traditionally for BRCA-mutated patients; Niraparib is often used regardless of BRCA status.
• Phase II vs. Phase III trials: Phase II looks for efficacy in a specific disease; Phase III compares a drug to the gold standard.
• X-rays vs. Gamma rays: X-rays are extranuclear; Gamma rays are nuclear in origin.
• 5-FU vs. Doxorubicin Toxicity: 5-FU and liposomal Doxorubicin both cause Hand-Foot Syndrome; However, Doxorubicin is uniquely cardiotoxic.
• Vincristine vs. Paclitaxel: Both cause neuropathy, but Vincristine prevents microtubule polymerization while Paclitaxel prevents depolymerization.
• Ionization vs. Excitation: Ionization removes an electron from an atom; Excitation merely moves it to a higher energy state.
• Amsterdam vs. Bethesda (Context): While not in this text, remember Bethesda is more sensitive for MSI testing while Amsterdam is specific for Lynch Syndrome.

QA

text

I. Principles of Radiation Therapy & Physics

1. Describe the mass and charge of Electromagnetic radiation. | No mass or charge.
   Travels at the speed of light.
2. What is the mathematical relationship in the inverse square law? | 1/r².
   Radiation energy per unit area is inversely proportional to the square of the distance.
3. Does fractional cell kill eliminate a constant number or fraction? | Constant fraction.
   Each dose kills a constant fraction of tumor cells.
4. What is the primary therapeutic goal of radiation? | Maximum local tumor control.
   While minimizing normal tissue damage and adverse symptoms.
5. List three factors associated with Radiation resistance. (3) | 1) Cellular hypoxia
   2) Nutritional deficiency
   3) Enhanced cell-mediated DNA repair
6. What are the most common Photons used in gynecologic malignancies? | X-rays and Gamma rays.
7. What is the origin of Gamma rays? | Atomic nucleus.
8. What is the origin of X-rays? | Extranuclear interactions.
   Specifically atomic orbital interactions.
9. How is Bremsstrahlung ("braking radiation") produced? | Accelerated electrons hit high-Z target.
   Generates photons of various energies.
10. What particles make up Particulate radiation? (4) | 1) Alpha particles
    2) Protons
    3) Neutrons
    4) Electrons
11. Describe the characteristic Bragg peak of Protons. | Peak dose at end.
    Dose is deposited at the end of the particle's range, sparing initial tissue.

II. Photon Interactions & Radiobiology

12. Energy level and effect of Coherent Scattering? | <10 keV.
    Results in no energy loss or radiobiologic effect.
13. Imaging relevance of the Photoelectric Effect (10-60 keV)? | High tissue-bone contrast.
    Involves total photon absorption and electron ejection.
14. Which interaction is predominant in human tissue (90% water)? | Compton Effect.
    Occurs at 60 keV to 10 MeV.
15. What is the most important interaction at therapeutic energies (4-18 MeV)? | Compton Effect.
16. What is the energy requirement for Pair Production? | >1.022 MeV.
    Results in an electron-positron pair; basis of PET imaging.
17. What causes two-thirds of Indirect DNA damage? | Hydroxyl radicals (OH).
    Formed from water.
18. Comparison of Sublethal DNA damage repair in normal vs. malignant cells? | More effective in normal cells.
    Malignant cells often have faulty genomic monitors.
19. Role of Intracellular molecular oxygen in DNA damage? | "Fixing" DNA damage.
    Required to fix damage caused by free radicals.
20. Consequence of tumor hypoxia on radiation? | Radiation resistance.
21. What is the oxygen-dependency of High-LET radiation cell death? | Independent of oxygenation.
    Densely ionizing (e.g., neutrons or alpha particles).
22. Mechanism and use of Amifostine? | Scavenges free radicals.
    Reduces cisplatin-induced renal toxicity in ovarian cancer.
23. What is the most common form of radiation-induced cell death? | Mitotic death.
    Occurs after the cell attempts to divide.

III. Tissue Sensitivity & The Cell Cycle

24. Why is the M phase (Mitosis) the most radiosensitive? | DNA is tightly packaged.
25. Why is the S phase (DNA Synthesis) the most radioresistant? | Presence of repair enzymes.
    Used during replication.
26. Relationship between proliferation rate and Radiosensitivity? | Highest in rapidly proliferating cells.
27. Relative radiosensitivity of G1 and G2 phases? | Intermediate.
    More sensitive than S phase, less than M phase.
28. Target Hemoglobin levels for cervical cancer radiation? | >10 mg/dL.
    Associated with improved tumor oxygenation and outcomes.

IV. Radiation Techniques: Teletherapy & Brachytherapy

29. Define the source location in Teletherapy (External Beam). | At a distance.
    Typically uses linear accelerators.
30. Benefit of Intensity-modulated radiotherapy (IMRT)? | Precision/Sparing normal tissues.
    Conforms high-dose region to tumor, sparing small bowel.
31. What do Isodose curves represent? | Points of equivalent dose.
32. Benefit of higher-energy beams (e.g., 22-MeV)? | Deeper penetration.
    Sparing the skin surface.
33. Define Brachytherapy (Internal) source placement. | Within or near tumor.
34. Common applicator for Intracavitary therapy in cervical cancer? | Fletcher-Suit applicator.
    Uses tandem and ovoids.
35. Administration details of High-dose rate (HDR) brachytherapy? | Outpatient basis.
    3 to 5 hours, repeated 3 to 6 times.
36. Requirements for Low-dose rate (LDR) brachytherapy? | Shielded room and bed rest.
    Source remains in place for an extended period.
37. Half-life of Cesium-137 (137Cs)? | 30 years.
38. Half-life of Iridium-192 (192Ir)? | 73.8 days.

V. Radiation Complications

39. Timing and targets of Acute radiation effects? | Days to weeks.
    Rapidly dividing tissues (skin, mucosa, bone marrow).
40. Cause of Late radiation effects (months to years)? | Vascular damage.
    And connective tissue loss (fibrosis, fistulas).
41. Management of Radiation cystitis? | Phenazopyridine.
    Presents as dysuria and frequency.
42. Symptoms of Sigmoiditis or enteritis? | Diarrhea and malabsorption.
    Includes cramping.
43. Management of Radiation-induced bowel symptoms? | Low-roughage diet.
    Also antispasmodics.
44. Timing and management of radiation-induced Fistulas? | 6 to 24 months.
    Often require surgical intervention.
45. Define Radiation recall dermatitis. | Skin reaction to chemo.
    Occurs after previous radiation (e.g., Dactinomycin).

VI. Chemotherapy Principles & Management

46. Standard of care for advanced ovarian cancer? | Taxane-platinum combination.
    Example: Paclitaxel + Carboplatin for six cycles.
47. Goal of Neoadjuvant chemotherapy? | Reduce tumor size.
    Improve likelihood of optimal debulking.
48. Purpose of Maintenance therapy? | Prolong stable disease.
    Given after initial primary treatment.
49. Management of the toxicity Myelosuppression? | G-CSF.
    Granulocyte colony-stimulating factor.
50. Standard metric for calculating chemotherapy doses? | Body Surface Area (BSA).
51. Function of RECIST criteria? | Standardized tumor measurement.
    Measuring response via imaging.
52. Definition of Platinum resistance? | Recurrence within <6 months.
    Progression after completing platinum therapy.
53. Definition of Platinum sensitivity? | Interval > 6 months.

VII. Chemotherapeutic Agents: Platinums & Taxanes

54. Key toxicity of Cisplatin? | Nephrotoxic.
    Requires aggressive hydration.
55. Side effects (3) of Cisplatin? | 1) Ototoxicity
    2) Severe N/V
    3) Neuropathy
56. Dosing method for Carboplatin? | Calvert formula (AUC).
57. Dose-limiting toxicity of Carboplatin? | Thrombocytopenia.
58. Mechanism and phase of Paclitaxel? | Stabilizes microtubules (M-phase).
    Derived from Yew trees.
59. Side effects (3) of Paclitaxel? | 1) Peripheral neuropathy
    2) Alopecia
    3) Hypersensitivity
60. Indication for Docetaxel? | Paclitaxel hypersensitivity.
61. Significant toxicity of Docetaxel? | Neutropenia.

VII. Chemotherapeutic Agents: Antibiotics & Topoisomerase

62. Use and phase action of Actinomycin D? | Used for GTD (G1 phase).
63. Toxicities (2) of Actinomycin D? | 1) Myelosuppression
    2) Radiation recall
64. Mechanism and color of Doxorubicin? | Inhibits topoisomerase II (Red color).
65. Toxicities (2) of Doxorubicin? | 1) Irreversible cardiotoxicity (CHF)
    2) Hand-foot syndrome
66. Mechanism of Bleomycin? | Single-strand breaks.
    Via hydroxyl radicals.
67. Unique feature and toxicity of Bleomycin? | NOT myelosuppressive.
    Causes pulmonary fibrosis.
68. Mechanism and toxicity of Topotecan? | Inhibits Topoisomerase I.
    Severe bone marrow suppression.
69. Mechanism and toxicity of Etoposide? | Inhibits Topoisomerase II.
    Myelosuppression.

VII. Chemotherapeutic Agents: Alkylating & Antimetabolites

70. Mechanism of Cyclophosphamide? | DNA cross-links.
71. Toxicity and prevention for Cyclophosphamide? | Hemorrhagic cystitis.
    Prevent with hydration and Mesna.
72. Mechanism of Methotrexate? | Inhibits dihydrofolate reductase.
    Folic acid analog.
73. Toxicities and rescue for Methotrexate? | Stomatitis/Hepatotoxicity.
    Rescue with Folinic acid.
74. Mechanism of 5-Fluorouracil? | Inhibits thymidylate synthase.
75. Toxicities (2) of 5-Fluorouracil? | 1) PPE (Hand-foot syndrome)
    2) Diarrhea

VII. Chemotherapeutic Agents: Vincas & Biologics

76. Mechanism of Vincristine? | Blocks microtubule polymerization.
77. Toxicities (2) of Vincristine? | 1) Severe neurotoxicity
    2) Constipation
78. Mechanism of Bevacizumab? | Monoclonal antibody targeting VEGF.
    Inhibits angiogenesis.
79. Toxicities (3) of Bevacizumab? | 1) Bowel perforation
    2) Hypertension
    3) Proteinuria

VIII. PARP Inhibitors & Hormones

80. Mechanism of PARP Inhibitors? | Synthetic lethality.
    Kills cells with deficient DNA repair (BRCA mutations).
81. First PARP inhibitor for BRCA-positive recurrent ovarian cancer? | Olaparib.
82. Benefit of Niraparib? | Consolidation regardless of BRCA status.
83. Indication for Rucaparib? | Platinum-sensitive recurrence.
    After failure of ≥2 lines of chemotherapy.
84. Best target for Hormonal therapy (Progestins)? | Well-differentiated endometrial carcinomas.

IX. Clinical Trials & Performance Status

85. Purpose of Phase I trials? | Safety and toxicity.
    Determines maximum tolerated dose.
86. Purpose of Phase II trials? | Therapeutic effectiveness.
    Against a specific tumor type.
87. Purpose of Phase III trials? | Compare to standard of care.
88. Poor candidate score for Karnofsky Performance Status? | Score ≤50.

X. Pregnancy & Radiation

89. Fetal risks of Fetal radiation exposure? | Malformations/Growth restriction.
    Also carcinogenesis.
90. Risks during Week 8 to 15 of gestation? | Intellectual disability.
    Threshold ~0.06 Gy.
91. Risks during Organogenesis (Weeks 2–8)? | Structural malformations.
    Threshold 0.1–0.2 Gy.
92. When is Radiotherapy to the maternal abdomen contraindicated? | After 25 weeks of gestation.
93. Condition for using Supradiaphragmatic radiotherapy in pregnancy? | Fetus must be shielded.

XI. Comparison of Similar Entities (Part 1)

94. Compare Cisplatin vs. Carboplatin nephrotoxicity. | Cisplatin is more nephrotoxic.
95. Compare Cisplatin vs. Carboplatin myelosuppression. | Carboplatin is more myelosuppressive.
96. Contrast Teletherapy vs. Brachytherapy source position. | Teletherapy: External source.
    Brachytherapy: Internal source.
97. Contrast Low-LET vs. High-LET oxygen requirement. | Low-LET (photons) requires oxygen.
    High-LET (alpha/neutrons) is oxygen-independent.
98. Contrast S-phase vs. M-phase radiosensitivity. | S-phase: Most radioresistant.
    M-phase: Most radiosensitive.
99. Contrast Acute vs. Late effects tissue types. | Acute: Rapidly dividing (skin/mucosa).
    Late: Slow-renewing (fibrosis/fistula).
100. Contrast Direct vs. Indirect Action. | Direct: Photon hits DNA.
     Indirect: Damage via hydroxyl radicals.

XI. Comparison of Similar Entities (Part 2)

101. Define Platinum-sensitive vs. Resistant based on time. | sensitive: >6 months.
     Resistant: <6 months.
102. Compare Paclitaxel vs. Docetaxel origin and toxicity. | Paclitaxel: Pacific Yew/Hypersensitivity.
     Docetaxel: English Yew/Neutropenic.
103. Compare Olaparib vs. Niraparib BRCA status use. | Olaparib: BRCA-mutated.
     Niraparib: Regardless of BRCA status.
104. Contrast Phase II vs. Phase III trials objective. | Phase II: Efficacy in a disease.
     Phase III: Comparison to gold standard.
105. Contrast X-rays vs. Gamma rays origin. | X-rays: Extranuclear.
     Gamma rays: Nuclear.
106. Compare 5-FU vs. Doxorubicin Toxicity on skin/heart. | Both: Hand-Foot Syndrome.
     Doxorubicin: Cardiotoxic.
107. Contrast Vincristine vs. Paclitaxel microtubule effect. | Vincristine: Prevents polymerization.
     Paclitaxel: Prevents depolymerization.
108. Contrast Ionization vs. Excitation. | Ionization: Removes electron.
     Excitation: Moves electron to higher state.
109. Amsterdam vs. Bethesda context for Lynch Syndrome? | Amsterdam: Specific for Lynch.
     Bethesda: Sensitive for MSI testing.

XII. Additional Detailed Parameters

110. Energy level of the Photoelectric Effect? | 10 to 60 keV.
111. Energy range of the Compton Effect? | 60 keV to 10 MeV.
112. Threshold for radiation-induced intellectual disability (8-15 weeks)? | ~0.06 Gy.
113. Threshold for radiation-induced structural malformations (2-8 weeks)? | 0.1–0.2 Gy.
114. Dactinomycin is associated with what radiation complication? | Radiation recall dermatitis.
115. What is the most common serious chemotherapy toxicity? | Myelosuppression.
116. Primary target of Bevacizumab? | VEGF (Vascular Endothelial Growth Factor).
117. Cyclophosphamide class of agent? | Alkylating agent.
118. Which antibiotic is red in color? | Doxorubicin.
119. Topotecan inhibits which Topoisomerase? | Topoisomerase I.
120. Etoposide inhibits which Topoisomerase? | Topoisomerase II.

4

Summary

text

I. General Principles of Lower Genital Tract Intraepithelial Neoplasia (LGTIN)

• Lower Genital Tract Intraepithelial Neoplasia (LGTIN) refers to a group of premalignant epithelial lesions characterized by dysplastic cellular changes confined to the epithelium of the cervix, vagina, and vulva without invasion of the basement membrane.
• In the pathology of LGTIN, Dysplasia is initially identified microscopically through nuclear and cytoplasmic changes before becoming grossly visible.
• The Lower Genital Tract specifically includes the vulva (external), vagina, and cervix.

II. Cervical Anatomy & The Transformation Zone (TZ)

• The Squamocolumnar Junction (SCJ) is a dynamic point that rarely remains at the external os, changing position in response to puberty, pregnancy, menopause, and hormones.
• In Neonates, the SCJ is located at the exocervix.
• During Menarche, estrogen causes glycogen accumulation, which lactobacilli convert to acid, stimulating normal physiological Squamous metaplasia in the squamocolumnar reserve cells.
• The ideal area for specimen collection for HPV or disease detection is the active squamocolumnar junction.

• The Transformation Zone is highly vulnerable to HPV because it is an area of active squamous metaplasia with high cell turnover where immature basal cells are exposed.

III. Classification of Cervical Intraepithelial Neoplasia (CIN)

• Atypical cells in CIN are microscopically characterized by:
  1. Increased nuclear-cytoplasmic ratio
  2. Increased nuclear size
  3. Loss of polarity
  4. Increased mitotic figures
  5. Hyperchromasia
• In the 2021 Bethesda System, Squamous Cell Abnormalities are divided into:
  • ASC-US: Atypical squamous cells of undetermined significance.
  • ASC-H: Atypical squamous cells, cannot exclude HSIL.
  • LSIL: Low-grade squamous intraepithelial lesion (includes CIN 1 and HPV effects).
  • HSIL: High-grade squamous intraepithelial lesion (includes CIN 2, CIN 3, and CIS).
• In the Bethesda System, Glandular Cell Abnormalities include:
  • AGC: Atypical glandular cells.
  • AIS: Endocervical adenocarcinoma in situ.
• LSIL is characterized by high viral replication with mild alteration in host cell growth, while HSIL involves low viral replication with high cellular dysregulation.

IV. Human Papillomavirus (HPV) Pathogenesis

• Genital HPV is the most common sexually transmitted infection (STI); nearly all sexually active individuals will acquire at least one type in their lifetime.
• HPV 16 is the most common high-risk oncogenic type; other high-risk types include HPV 18, 31, 33, 45, 52, and 58.
• HPV 6 and 11 are low-risk types primarily associated with genital warts (condyloma acuminata).
• For malignancy to occur, the single most important step is Persistent infection with high-risk HPV and failure of host immune clearance.
• During Oncogenic infection, viral DNA integrates into the host genome, which disrupts the E2 gene; because E2 normally suppresses E6 and E7, its loss leads to uncontrolled oncoprotein expression.

• Koilocytosis, characterized by nuclear enlargement and perinuclear clearing, is a hallmark cellular change of early/low-grade HPV lesions.

V. Screening and Risk Factors

• Factors increasing Risk for HPV/CIN include:
  1. Young age at first intercourse
  2. Multiple sex partners
  3. Male partner with multiple partners
  4. Smoking (local immunosuppression)
  5. Nutritional deficiencies
• ACOG/USPSTF Screening Guidelines for average-risk women:
  • Ages 21–24: Cytology (Pap) alone every 3 years.
  • Ages 25–29: Preferred Primary HR-HPV testing every 5 years (ACS) or Pap alone every 3 years.
  • Ages 30–65: Preferred Primary HR-HPV testing every 5 years OR co-testing (Pap + HPV) every 5 years.
• Screening may be Discontinued at age >65 if there is "adequate prior screening" (2 negative HPV/Co-tests or 3 negative Pap tests in 10 years) and no history of CIN 2+ in the last 25 years.
• DES (Diethylstilbestrol) Exposure in utero requires annual cytology due to increased risk of clear cell adenocarcinoma.
• Liquid-based cytology (LBC) (e.g., ThinPrep) was developed to reduce contamination (blood/mucus) and provide more representative samples compared to conventional Pap smears.

VI. Diagnostic Evaluation

• Colposcopy is a low-power binocular microscope exam of the cervix used after abnormal cytology; it is considered "Satisfactory" only if the entire transformation zone is visualized.
• Acetowhite Epithelium appears when 3%–5% acetic acid is applied, coagulating nuclear proteins in dysplastic cells to reflect light.
• Leukoplakia is a white plaque visible on the cervix before the application of acetic acid, caused by a keratin layer.
• Punctation refers to dilated capillaries appearing as dots on the surface; when found in acetowhite areas, they often indicate CIN.
• Schiller’s Test (VILI) uses Lugol's iodine; normal cells (rich in glycogen) stain mahogany brown, while dysplastic cells remain unstained (yellow/pale).
• Endocervical Curettage (ECC) is recommended if the colposcopic exam is unsatisfactory or if there is abnormal cytology without a visible lesion.

VII. Management of Cervical Lesions

• Cryotherapy destroys the surface epithelium by crystallizing intracellular water using Nitrous oxide (-89°C) or CO2 (-65°C); it requires a 3–5–3 double freeze–thaw cycle.
• Cryotherapy Criteria: Acceptable for persistent CIN 1 (24 months) or CIN 2 if the lesion is small, ectocervical, and the ECC is negative.
• Laser Ablation uses a CO2 laser to vaporize tissue to a depth of ~5 mm; it produces no prolonged discharge but provides no tissue specimen.
• Loop Electrosurgical Excision Procedure (LEEP/LLETZ) is the most common US treatment for CIN 2/3; it uses a wire loop to excise the TZ and provide a tissue specimen for pathology.
• Cold Knife Conization (CKC) is an excisional procedure done with a scalpel in an OR; it is preferred for Glandular abnormalities (AIS) or suspected invasive cancer because it avoids thermal artifact on margins.
• Hysterectomy is a treatment of last resort for CIN, indicated for microinvasion, recurrent high-grade CIN, or if other gynecologic issues (e.g., fibroids/prolapse) coexist.

VIII. Vaginal and Vulvar Intraepithelial Neoplasia (VaIN & VIN)

• Vaginal Intraepithelial Neoplasia (VaIN) is most commonly found in the upper third of the vagina and is frequently associated with a history of CIN or cervical cancer.
• VaIN Management: VaIN 1 is monitored via surveillance; VaIN 2 and 3 require treatment (excision or ablation) due to a 2%–5% progression risk to invasive cancer.
• Usual-type VIN (uVIN/HSIL) is the most common form of vulvar neoplasia, caused by high-risk HPV (HPV 16), seen in younger women, and often multifocal.
• Differentiated-type VIN (dVIN) is NOT HPV-related; it is associated with chronic inflammation (lichen sclerosus), occurs in older women, and has a higher risk of progression to squamous cell carcinoma.
• Symptoms of Vulvar Intraepithelial Neoplasia (VIN) include pruritus (itching), burning, and visible color changes (white, red, or pigmented); many remain asymptomatic.
• Imiquimod cream is a topical immune response modifier used for VIN and genital warts; Trichloroacetic acid is used for pregnant women with external warts.

IX. Prophylaxis: HPV Vaccines

• HPV Vaccines work by stimulating neutralizing antibodies; they are prophylactic and cannot treat existing HPV disease or cancer.
• Total abstinence from all genital contact is the most effective prevention method for HPV.

X. Comparison of Similar Entities

• LSIL vs. HSIL Natural History: 60% of LSIL regresses and only 10% progresses to carcinoma, whereas 30% of HSIL regresses and 10% progresses to carcinoma.
• CIN 1 vs. CIN 3 Involvement: CIN 1 involves the lower 1/3 of the epithelium thickness, while CIN 3 involves the full thickness of the epithelium.
• uVIN vs. dVIN Etiology: uVIN is caused by oncogenic HPV (mainly type 16), whereas dVIN is associated with chronic inflammatory conditions like Lichen Sclerosus and is HPV-negative.
• Ablative vs. Excisional Therapy: Ablative therapies (Cryo/Laser) destroy tissue and provide no specimen, while excisional therapies (LEEP/CKC) provide a tissue specimen to rule out invasive cancer.
• LEEP vs. Cold Knife Conization (CKC): LEEP is done in-office with thermal energy (risk of thermal artifact), whereas CKC is done in the OR with a scalpel (preferred for AIS and margin assessment).
• E6 vs. E7 Oncoproteins: E6 binds and degrades p53 (stopping apoptosis), while E7 inactivates Rb (allowing continuous cell cycling).
• Acetowhite vs. Leukoplakia: Acetowhite epithelium only appears after acetic acid application; Leukoplakia is white before any solution is applied.
• Surgical vs. Medical VIN Treatment: Surgical excision/laser is used for localized or suspected invasive VIN, while Imiquimod is a medical topical therapy used for diffuse disease.
• Pregnancy vs. Non-pregnancy CIN Management: In pregnancy, CIN is usually managed expectantly and ECC is contraindicated; postpartum, many low-grade lesions regress.
• Bivalent vs. Quadrivalent Vaccine: Bivalent (16, 18) only covers cancer-causing types, whereas Quadrivalent (6, 11, 16, 18) covers both cancer and genital warts.
• Cytology Sensitivity vs. HPV Testing: Standard Pap smear has lower sensitivity (~51%) compared to HR-HPV testing, leading to the preference for HPV testing in modern screening.

QA

text

I. General Principles of LGTIN

1. Describe Lower Genital Tract Intraepithelial Neoplasia (LGTIN). | Premalignant lesions with dysplastic changes.
2. Where are cellular changes confined in LGTIN? | Epithelium (no basement membrane invasion).
3. Anatomy: Components of the Lower Genital Tract? (3) | Vulva, Vagina, and Cervix.
4. How is Dysplasia initially identified in the pathology of LGTIN? | Microscopically (nuclear and cytoplasmic changes).
5. At what point does Dysplasia in LGTIN become grossly visible? | After microscopic nuclear/cytoplasmic changes occur.

II. Cervical Anatomy & The Transformation Zone (TZ)

6. Location: Columnar Epithelium? | Lines the endocervical canal.
7. Location: Squamous Epithelium? | Covers the exocervix.
8. What is the meeting point of Columnar and Squamous epithelium? | Squamocolumnar Junction (SCJ).
9. Physiology: Columnar Epithelium? | Secretes mucus; undergoes metaplasia.
10. Physiology: Squamous Epithelium? | Protective outer layer.
11. Describe the nature of the Squamocolumnar Junction (SCJ) position. | Dynamic point (rarely at external os).
12. Factors changing the Squamocolumnar Junction (SCJ) position? (4) | Puberty, pregnancy, menopause, and hormones.
13. Where is the SCJ located in neonates? | Exocervix.
14. Effect of estrogen on glycogen in Menarche? | Causes glycogen accumulation.
15. Role of lactobacilli in Squamous metaplasia during menarche? | Converts glycogen to acid.
16. Target of Squamous metaplasia stimulus? | Squamocolumnar reserve cells.
17. Ideal area for HPV or disease detection collection? | Active squamocolumnar junction.
18. Estrogen level: Premenarchal stage? | Low.
19. SCJ Location: Premenarchal stage? | Inside the endocervical canal.
20. Transformation Zone (TZ): Premenarchal stage? | Absent or minimal.
21. Estrogen level: Reproductive stage? | Normal.
22. SCJ Location: Reproductive stage? | Ectocervix.
23. Transformation Zone (TZ): Reproductive stage? | Active and visible.
24. Estrogen level: Pregnancy? | Very High.
25. SCJ Location: Pregnancy? | Widely everted on ectocervix.
26. Transformation Zone (TZ): Pregnancy? | Large and exposed.
27. Estrogen level: Postmenopausal stage? | Low.
28. SCJ Location: Postmenopausal stage? | Regressed inside the canal.
29. Transformation Zone (TZ): Postmenopausal stage? | Regressed/difficult to see.
30. Why is the Transformation Zone highly vulnerable to HPV? | Active metaplasia with high turnover.
31. Cells exposed in the Transformation Zone during metaplasia? | Immature basal cells.

III. Classification of Cervical Intraepithelial Neoplasia (CIN)

32. Epithelial thickness involved: CIN 1? | Atypical cells in < 1/3 thickness.
33. Former dysplasia term: CIN 1? | Mild Dysplasia.
34. Epithelial thickness involved: CIN 2? | 1/3 to 2/3 thickness.
35. Former dysplasia term: CIN 2? | Moderate Dysplasia.
36. Epithelial thickness involved: CIN 3? | Full thickness of epithelium.
37. Former terms (2) for CIN 3? | Severe Dysplasia / Carcinoma in Situ.
38. Microscopic characteristics: Atypical cells in CIN? (5) | 1) High N:C ratio
    2) Large nuclei
    3) Loss of polarity
    4) Mitotic figures
    5) Hyperchromasia.
39. Full name of ASC-US? | Atypical squamous cells of undetermined significance.
40. Full name of ASC-H? | Atypical squamous cells, cannot exclude HSIL.
41. Components included in LSIL? (2) | CIN 1 and HPV effects.
42. Components included in HSIL? (3) | CIN 2, CIN 3, and CIS.
43. Full name of AGC? | Atypical glandular cells.
44. Full name of AIS? | Endocervical adenocarcinoma in situ.
45. Pathogenesis of LSIL? | High viral replication; mild host cell alteration.
46. Pathogenesis of HSIL? | Low viral replication; high cellular dysregulation.

IV. Human Papillomavirus (HPV) Pathogenesis

47. Significance of Genital HPV among STIs? | Most common sexually transmitted infection.
48. Most common high-risk oncogenic HPV type? | HPV 16.
49. List of high-risk HPV types (6)? | 18, 31, 33, 45, 52, and 58.
50. Common low-risk HPV types? (2) | HPV 6 and 11.
51. Condition associated with HPV 6 and 11? | Genital warts (condyloma acuminata).
52. Essential step for malignancy in HPV infection? | Persistent infection.
53. Host factor preventing HPV malignancy? | Host immune clearance.
54. Gene disrupted by HPV DNA integration into host genome? | E2 gene.
55. Result of E2 gene loss in HPV? | Uncontrolled oncoprotein expression (E6/E7).
56. Target of E6 Oncoprotein? | p53 tumor suppressor.
57. Mechanism of E6 Oncoprotein? | Degrades p53; inhibits apoptosis.
58. Target of E7 Oncoprotein? | Retinoblastoma (Rb) protein.
59. Mechanism of E7 Oncoprotein? | Inactivates Rb; uncontrolled G1 to S phase.
60. Cell cycling effect of E7 Oncoprotein? | Continuous cell cycling.
61. Hallmark cellular changes of Koilocytosis? (2) | Nuclear enlargement and perinuclear clearing.
62. Koilocytosis is typical for which grade of HPV lesions? | Early or low-grade.

V. Screening and Risk Factors

63. Risk factors (5) for HPV/CIN? | 1) Young age coitus
    2) Multiple partners
    3) Male partner habits
    4) Smoking
    5) Nutritional deficiencies.
64. Screening ages 21–24: ACOG Guidelines? | Cytology (Pap) alone every 3 years.
65. Preferred screening ages 25–29: ACS/ACOG? | Primary HR-HPV testing every 5 years.
66. Option for ages 25–29: ACOG Screening? | Pap alone every 3 years.
67. Preferred screening ages 30–65? (2 options) | Primary HR-HPV every 5 years OR co-testing every 5 years.
68. When can Screening be discontinued (age)? | >65 years.
69. Criteria for Adequate prior screening at age 65? (2 options) | 2 negative HPV/Co-tests OR 3 negative Paps (in 10 years).
70. History clause to discontinue Screening at age 65? | No CIN 2+ in last 25 years.
71. Screening requirement for DES Exposure? | Annual cytology.
72. Cancer risk associated with DES Exposure? | Clear cell adenocarcinoma.
73. Goal of Liquid-based cytology (LBC) development? | Reduce contamination (blood/mucus).

VI. Diagnostic Evaluation

74. Describe Colposcopy. | Low-power binocular microscope exam of cervix.
75. Requirement for a Satisfactory Colposcopy? | Entire transformation zone visualized.
76. What causes Acetowhite Epithelium? | 3%–5% acetic acid application.
77. Mechanism of Acetowhite Epithelium? | Coagulates nuclear proteins to reflect light.
78. What is Leukoplakia? | White plaque visible before acetic acid.
79. Cause of Leukoplakia? | Keratin layer.
80. Describe Punctation on the cervix. | Dilated capillaries appearing as dots.
81. Clinical significance of Punctation in acetowhite areas? | Often indicates CIN.
82. Solution used in Schiller’s Test (VILI)? | Lugol’s iodine.
83. Appearance of normal cells in Schiller’s Test? | Mahogany brown (rich in glycogen).
84. Appearance of dysplastic cells in Schiller’s Test? | Yellow/pale (unstained).
85. Recommendation for Endocervical Curettage (ECC)? | Unsatisfactory colposcopy or abnormal cytology without lesion.

VII. Management of Cervical Lesions

86. Define Cryotherapy mechanism. | Crystallizing intracellular water to destroy epithelium.
87. Agents used in Cryotherapy? (2) | Nitrous oxide or CO2.
88. Required cycle for Cryotherapy? | 3–5–3 double freeze–thaw cycle.
89. When is Cryotherapy acceptable? (3) | Persistent CIN 1 (24 mo), small CIN 2, negative ECC.
90. Describe Laser Ablation depth? | Vaporizes tissue to ~5 mm.
91. Disadvantage of Laser Ablation? | Provides no tissue specimen.
92. Most common treatment for CIN 2/3 in the US? | Loop Electrosurgical Excision Procedure (LEEP).
93. Benefit of LEEP/LLETZ? | Provides tissue specimen for pathology.
94. Preferred procedure for Glandular abnormalities (AIS)? | Cold Knife Conization (CKC).
95. Why is CKC used for suspected invasive cancer? | Avoids thermal artifact on margins.
96. Indication for Hysterectomy in CIN? (3) | Microinvasion, recurrent high-grade CIN, or coexisting gyn issues.

VIII. Vaginal and Vulvar Intraepithelial Neoplasia (VaIN & VIN)

97. Common location: Vaginal Intraepithelial Neoplasia (VaIN)? | Upper third of the vagina.
98. Common association for VaIN? | Prior history of CIN or cervical cancer.
99. Management: VaIN 1? | Surveillance.
100. Management: VaIN 2 and 3? | Excision or ablation.
101. Risk of progression for untreated VaIN 2/3? | 2%–5% to invasive cancer.
102. Most common form of vulvar neoplasia? | Usual-type VIN (uVIN/HSIL).
103. Etiology: Usual-type VIN? | High-risk HPV (mainly HPV 16).
104. Typical patient profile: uVIN? | Younger women.
105. Etiology: Differentiated-type VIN (dVIN)? | Chronic inflammation (Lichen Sclerosus); HPV-negative.
106. Progression risk: dVIN vs uVIN? | dVIN has higher progression risk to SCC.
107. Symptoms (3): Vulvar Intraepithelial Neoplasia (VIN)? | Pruritus, burning, visible color changes.
108. Medical use: Imiquimod cream? | Topical immune response modifier for VIN/warts.
109. Treatment for external warts in pregnant women? | Trichloroacetic acid.

IX. Prophylaxis: HPV Vaccines

110. HPV types covered: Bivalent (Cervarix)? | 16 and 18.
111. HPV types covered: Quadrivalent (Gardasil)? | 6, 11, 16, and 18.
112. HPV types covered: 9-valent (Gardasil 9)? | 6, 11, 16, 18, 31, 33, 45, 52, 58.
113. Goal: Bivalent Vaccine? | Cervical cancer prevention.
114. Goal: Quadrivalent Vaccine? | Cancer and Genital Warts prevention.
115. Benefit: 9-valent Vaccine? | Broadest cancer and wart protection.
116. Mechanism: HPV Vaccines? | Stimulating neutralizing antibodies.
117. Limitation: HPV Vaccines? | Prophylactic only (cannot treat existing disease).
118. Most effective HPV prevention method? | Total abstinence from genital contact.

X. Comparison of Similar Entities

119. Natural history: LSIL regression rate? | 60%.
120. Natural history: HSIL regression rate? | 30%.
121. Natural history: Carcinoma progression in LSIL vs HSIL? | 10% for both.
122. Compare epithelial thickness: CIN 1 vs. CIN 3? | CIN 1: lower 1/3; CIN 3: full thickness.
123. Etiology: uVIN vs dVIN? | uVIN: Oncogenic HPV; dVIN: HPV-negative/Lichen Sclerosus.
124. Therapy contrast: Ablative vs Excisional? | Ablative: no specimen; Excisional: provides specimen.
125. Feature: LEEP artifact risk? | Thermal artifact.
126. Procedure choice: AIS or margin assessment? | Cold Knife Conization (CKC).
127. Function: E6 vs E7? | E6 degrades p53 (stops apoptosis); E7 inactivates Rb (allows cell cycle).
128. Identification timing: Acetowhite vs Leukoplakia? | Acetowhite: after acid; Leukoplakia: before acid.
129. VIN treatment: Surgical vs Medical usage? | Surgical: localized/invasive; Medical (Imiquimod): diffuse disease.
130. Management difference: Pregnancy vs Non-pregnancy CIN? | Pregnancy: expectant management; ECC is contraindicated.
131. Vaccine coverage: Bivalent vs Quadrivalent? | Bivalent: cancer types; Quadrivalent: cancer + warts.
132. Sensitivity: Cytology vs HR-HPV Testing? | Cytology lower (~51%) than HR-HPV.